Clinical Trial: SWOG S1609

SWOG S1609

Status: Closed

NCT#02834013

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

S1609 is permanently closed to accrual, effective March 15, 2023.

The Montana Cancer Consortium (MCC) is an independent nonprofit organization whose mission is to bring state-of-the-art cancer care to Montana, Idaho and Wyoming through National Cancer Institute (NCI) sponsored clinical research.

Navigation

About Us

Contact Us

Copyright © Montana Cancer Consortium | All rights reserved